文献速递围术期管理与 ERAS

胸外科加速康复外科项目持续减少出院阿片类处方:多水平广义线性模型

Sustained reduction of discharge opioid prescriptions in an enhanced recovery after thoracic surgery program: A multilevel generalized linear model.
PubMed 文献 · Surgery · 2021-11-02

该回顾性队列纳入2016年3月至2020年4月胸外科加速康复外科项目下2081例手术患者,采用多水平广义线性模型分析出院阿片类处方趋势。出院阿片类处方率从2016年3月的35%降至2020年4月的25%,处方量从184±321吗啡当量日剂量降至94±251吗啡当量日剂量,呈持续下降趋势(β -11.8吗啡当量日剂量/年,P = .048),且与微创手术使用正相关。

要点

  • 胸外科加速康复外科项目下出院阿片类处方率从35%降至25%,处方量从184±321降至94±251吗啡当量日剂量。
  • 多水平模型显示阿片类处方呈持续下降趋势(β -11.8吗啡当量日剂量/年,P = .048)。
  • 微创手术与阿片类处方量负相关:电视辅助胸腔镜手术β -84.9(P < .001),机器人辅助胸外科手术β -139.2(P < .001)。

核心结论

  • 胸外科加速康复外科项目促成出院阿片类处方持续减少,该减少与项目实施时间及微创手术技术使用正相关,但受术中阿片类给药量负面影响。

研究设计与样本

  • 回顾性队列研究,纳入2016年3月至2020年4月4年胸外科加速康复外科项目下2081例胸外科手术患者。
  • 采用多水平广义线性模型校正外科医生差异和胸科切除类型。

主要发现

  • 出院阿片类处方率从2016年3月的35%降至2020年4月的25%。
  • 处方阿片类量从184±321吗啡当量日剂量降至94±251吗啡当量日剂量。
  • 多水平模型显示阿片类处方持续下降趋势(β -11.8吗啡当量日剂量/年,P = .048)。
  • 微创手术与阿片类处方量负相关:电视辅助胸腔镜手术β -84.9吗啡当量日剂量(P < .001),机器人辅助胸外科手术β -139.2吗啡当量日剂量(P < .001)。
  • 术中阿片类给药量β -1.4吗啡当量日剂量/每1吗啡当量剂量(P = .026),术后对乙酰氨基酚量β -18.2吗啡当量日剂量/每1 g(P = .026)。

关键数值与推荐

  • 出院阿片类处方定义为氢可酮、氢吗啡酮和羟考酮处方。
  • 阿片类处方总量以吗啡当量日剂量表示。
  • 持续减少的出院阿片类处方未影响30天内再入院率(比值比1.17,95%置信区间0.86-1.59,P = .306)。
  • 亚组分析显示氢吗啡酮处方持续显著减少(β -10.9吗啡当量日剂量/年,P = .004),氢可酮(β -5.7吗啡当量日剂量/年,P = .168)和羟考酮(β +4.78吗啡当量日剂量/年,P = .183)无显著变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Enhanced Recovery After Surgery programs have been shown to effectively reduce opioid prescriptions at discharge after their implementation in several institutions, but little is known regarding the sustainability of this effect. Understanding opioid prescribing patterns after long-term implementation of Enhanced Recovery After Surgery initiatives may help guide further opioid prescription reduction and improvements. Our group aimed to determine whether reductions in opioid prescriptions at discharge are sustained in an Enhanced Recovery After Surgery program for thoracic surgery. METHODS: This retrospective cohort included 2,081 patients undergoing thoracic surgery within a 4-year Enhanced Recovery After Surgery program from March 2016 through April 2020. Our Enhanced Recovery After Surgery protocol included a standardized multimodal analgesic regimen (ie, preoperative gabapentin, tramadol, intercostal nerve block with liposomal bupivacaine, and intraoperative acetaminophen, and ketorolac) and the rest of the interventions recommended by the Enhanced Recovery After Surgery society guidelines. Our primary outcomes were the presence of opioid prescriptions at discharge (hydrocodone, hydromorphone, and oxycodone) and the total opioid amount prescribed (morphine equivalent daily dose). Multilevel generalized linear models were used to account for surgeon variabilities and types of thoracic resection. RESULTS: Over the study period, the rate of opioid prescriptions at discharge reduced from 35% (Mar 2016) to 25% (Apr 2020), and the amount of opioid prescribed declined from 184 ± 321 morphine equivalent daily dose to 94 ± 251 morphine equivalent daily dose. In multilevel generalized linear models, there was a sustained downward trend in opioid prescriptions over the study period (β -11.8 morphine equivalent daily dose per year, P = .048), which was also directly correlated with the use of minimally invasive surgery (β -84.9 morphine equivalent daily dose for video-assisted thoracoscopic surgery, P < .001; β -139.2 morphine equivalent daily dose for robotic-assisted thoracic surgery, P < .001), intraoperative opioid administration (β -1.4 morphine equivalent daily dose per 1 morphine equivalent dose, P = .026), and the amount of postoperative acetaminophen (β -18.2 morphine equivalent daily dose per 1 g, P = .026). The sustained reduction of opioid prescriptions at discharge did not impact hospital readmission rates within 30 days (odds ratio 1.17, 95% confidence interval 0.86-1.59, P = .306). Subgroup analysis showed a significant, sustained decrease in hydromorphone (β -10.9 morphine equivalent daily dose per year, P = .004), but not for hydrocodone prescriptions (β -5.7 morphine equivalent daily dose per year, P = .168) or oxycodone (β +4.78 morphine equivalent daily dose per year, P = .183). CONCLUSION: Our Enhanced Recovery After Surgery program for thoracic surgery contributed to a sustained reduction of opioid prescriptions at discharge, which positively correlated with the duration of its implementation and the use of minimally invasive surgical techniques but was negatively impacted by the amount of intraoperative opioid administration.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Zorrilla-Vaca A, Rice D, Brown JK, et al. Sustained reduction of discharge opioid prescriptions in an enhanced recovery after thoracic surgery program: A multilevel generalized linear model. Surgery. 2021. PMID: 34740455. doi:10.1016/j.surg.2021.08.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。